European Network for Genetic and Genomic Epidemiology
ENGAGE (European Network for Genetic and Genomic Epidemiology) has, as its central objective, the translation of the wealth of data emerging from large-scale research efforts in molecular epidemiology into information of direct re...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
CGL2011-27866
VARIABILIDAD POBLACIONAL DE REGIONES GENOMICAS IDENTIFICADAS...
97K€
Cerrado
BIG_IDEA
Building an Integrated Genetic Infectious Disease Epidemiolo...
1M€
Cerrado
MTM2008-02457
MODELOS Y METODOS ESTADISTICOS PARA EL ANALISIS DE DATOS CUA...
19K€
Cerrado
SAF2009-12304
GEWIMICS (GENEENVWIDEINTERACTMETAOMICS): DESARROLLO Y VALIDA...
24K€
Cerrado
EpiGen Ethiopia
BUILDING SCALABLE PATHOGEN GENOMIC EPIDEMIOLOGY FOR ETHIOPIA
5M€
Cerrado
Información proyecto ENGAGE
Líder del proyecto
HELSINGIN YLIOPISTO
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
16M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
ENGAGE (European Network for Genetic and Genomic Epidemiology) has, as its central objective, the translation of the wealth of data emerging from large-scale research efforts in molecular epidemiology into information of direct relevance to future advances in clinical medicine. ENGAGE will do this through the integration of very large-scale genetic and phenotypic data already available from a substantial number of large and well-characterised European (and other) sample sets of various types. The initial focus will be an integrated analysis of >80,000 genomewide association scans available to the consortium, thereby identifying the large number of novel disease-susceptibility variants undetectable in individual studies. Early studies will concentrate on metabolic and cardiovascular phenotypes, with subsequent expansion to apply the methods developed and lessons learned in other disease areas. The ENGAGE framework has been designed to be adaptable to advances that enable global analyses of other sources of genomic variation (eg structural and epigenetic variants), and to broadening of the phenotypic spectrum (to genomic endophenotypes in particular). The clinical and public health relevance of the novel disease- and trait-susceptibility variants we identify will be evaluated using the breadth and diversity of ENGAGE cohorts (DNAs and serum/plasma samples from over 600,000 individuals). The final step will be to effect responsible clinical translation of our major findings. As well as advances in the understanding of disease pathogenesis which may underpin novel therapeutic advances, we expect to provide clear proof-of-principle that genetic and genomic discoveries can be translated into diagnostic indicators for common diseases with the capacity to stratify risk, monitor disease progression and predict and monitor therapeutic response. ENGAGE has assembled the best researchers, clinical samples and statistical and technical expertise in Europe to realise these goals.